Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Quality Of Life in Prostate Cancer Patients Initiating Triptorelin (QOCPIT)

16 de noviembre de 2026 actualizado por: Ipsen

QOCPIT (Quality Of Life in Prostate Cancer Patients Initiating Triptorelin): A Prospective Observational Study to Evaluate Baseline Factors That Stabilize or Improve Health-related Quality of Life.

Prostate cancer and its treatment, particularly androgen deprivation therapy (ADT) may affect different aspects of a person's quality of life, including physical well-being and daily activities.

The purpose of this study is to evaluate baseline factors that stabilize or improve quality of life in patients with prostate cancer who are initiating triptorelin treatment as ADT, in routine clinical practice.

Participants in this study will be patients with prostate cancer whose treating physician has decided to initiate treatment with triptorelin.

This is an observational study. No treatment will be assigned as part of the study, and all medical decisions will be made by the treating physician according to routine clinical practice.

Participants will be followed for approximately 6 months. Information collected during the study may include demographics and medical characteristics, prostate cancer and treatments characteristics, physical activity, supportive care and quality of life. Questionnaires about quality of life and physical activity will be completed by participants at the start of the study and again approximately 6 months later. Information on adverse events occurring during the study will also be collected.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Tipo de estudio

De observación

Inscripción (Estimado)

819

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Masculino

Método de muestreo

Muestra no probabilística

Población de estudio

Adult males with prostate cancer initiating triptorelin treatment in routine clinical practice and meeting the study eligibility criteria.

Descripción

Inclusion Criteria:

Patients are eligible to be included in the study only if all the following criteria apply:

  1. Males ≥18 years old.
  2. Patient with histologically confirmed PCa.
  3. Patient eligible to start triptorelin in its labelled indication for at least 6 months and for whom the decision to start triptorelin was made voluntarily by the physician as part of routine medical practice, prior to the inclusion in the study.
  4. Patient able to understand and complete study-related questionnaires.
  5. Patient having been informed and not opposed to participating in the study.
  6. Patient covered by healthcare insurance.

Exclusion Criteria

Patients will not be included in the study if they meet any of the following criteria:

  1. Patient currently participating in any interventional clinical trial.
  2. Patient who received a hormonal treatment during the last 6 months before inclusion (or hormonal treatment whose duration of action may impact the 6 months before inclusion).
  3. Patient under tutorship or curatorship; patients under safeguard of justice or deprived of his liberty by an administrative or court decision.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
Identification of baseline factors including: demographic, clinical, disease and treatment factors, associated with stabilization (change:]-10; 10[) or improvement (change ≥10) of Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score
Periodo de tiempo: At 6 months
At 6 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Participants' baseline demographic characteristics
Periodo de tiempo: At baseline

Including:

  • Age.
  • Partnership status.
  • Employment status.
  • Area of residence.
  • Socioeconomic status.
At baseline
Participants' clinical characteristics at baseline
Periodo de tiempo: At baseline

Including:

  • BMI
  • Eastern Cooperative Oncology Group (ECOG) Performance status score.
  • G8 score if applicable.
  • Comorbidity status, medical and surgical history, and systemic treatments for comorbidities.
  • Participant's level of physical activity, using IPAQ questionnaire.
At baseline
Prostate cancer characteristics at diagnosis and baseline
Periodo de tiempo: At baseline

Including:

  • Prostate Cancer (PCa) presentation (new diagnosis or recurrence/progression) at baseline.
  • Gleason score/International Society of Urological Pathology (ISUP) group
  • TNM (Tumor Node Metastasis) at diagnosis.
  • Prostate Specific Antigen (PSA) and testosterone levels at PCa diagnosis.
  • Previous treatments received for PCa, if any.
At baseline
Participants symptoms at baseline
Periodo de tiempo: At baseline
At baseline
Participants' PCa treatment patterns at baseline
Periodo de tiempo: At baseline
  • Triptorelin treatment modalities
  • Radiotherapy modalities
  • Associated systemic PCa treatments
At baseline
Participants' healthcare pathway/supportive care done or planned
Periodo de tiempo: At baseline

Including:

  • Pretreatment assessments
  • Visits to supportive health care professionals done or planned.
  • Participation in a dedicated healthcare pathway (as a one-day hospital stay with visits to several healthcare professionals).
  • Associated prescriptions or recommendations
  • Complementary information on cancer patient organizations and/or websites.
At baseline
Evolution of PCa at 6-month follow-up according to investigator's opinion
Periodo de tiempo: At 6 months

Evolution of PCa at 6-month follow-up according to investigator's opinion: control / stable / progression.

At 6 months
Symptoms and biological characteristics at 6 months
Periodo de tiempo: At 6 months
At 6 months
Participant's level of physical activity, using International Physical Activity Questionnaire (IPAQ) questionnaire
Periodo de tiempo: At 6 months

The International Physical Activity Questionnaire (IPAQ) is a participant-reported questionnaire used to assess physical activity level. Higher scores indicate higher levels of physical activity.

At 6 months
Participants' Quality Of life (QoL)
Periodo de tiempo: At baseline and at 6 months
  • FACT-P total score, sub-scores and individual items, at baseline and at 6- month follow-up, and their changes from baseline.
  • European Organisation for Research and Treatment of CancerQuality-of-Life Questionnaire Prostate Module (EORTC QLQ-PR25) sexual activity individual items and domain scores at baseline and at 6-month follow-up and changes from baseline.
At baseline and at 6 months
Participants' PCa treatment patterns at 6 months
Periodo de tiempo: At baseline and at 6 months
  • Collection of triptorelin administrations from initiation
  • Radiotherapy modalities in case of changes,
  • Associated systemic PCa treatments in case of changes.
At baseline and at 6 months
Participants' healthcare pathway/supportive care at 6 months
Periodo de tiempo: At 6 months

• Participant's healthcare pathway/type of supportive care in case of changes.

At 6 months
Identification of factors associated with participant's quality of life
Periodo de tiempo: At 6 months

• Identification of baseline factors, including demographic, clinical, disease and treatment factors, associated with stabilization (change: ]-3;3[) or improvement (change ≥3) of Physical Well-Being (PWB) and Prostate Cancer Specific (PCS) sub-scores of FACT-P at 6 months after inclusion, using a logistic model.

At 6 months
Percentage of participants with adverse events
Periodo de tiempo: From enrollment to Month 6

An adverse event (AE) is any untoward medical occurrence in a participant. The percentage of participants experiencing at least one adverse event, including cardiovascular events occurring after initiation of triptorelin treatment, will be assessed during study follow-up.

From enrollment to Month 6

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Ipsen Medical Director, Ipsen

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

23 de noviembre de 2026

Finalización primaria (Estimado)

25 de febrero de 2028

Finalización del estudio (Estimado)

30 de octubre de 2028

Fechas de registro del estudio

Enviado por primera vez

16 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Publicado por primera vez (Actual)

20 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

20 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Marco de tiempo para compartir IPD

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Criterios de acceso compartido de IPD

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir